Caribou Biosciences
CRBU
144 hedge funds and large institutions have $402M invested in Caribou Biosciences in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 12 closing their positions.
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
71% more call options, than puts
Call options by funds: $544K | Put options by funds: $319K
19% more capital invested
Capital invested by funds: $338M → $402M (+$63.7M)
14% more funds holding
Funds holding: 126 → 144 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.8% less ownership
Funds ownership: 80.17% → 79.37% (-0.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$7.26M |
| 2 |
BlackRock
New York
|
+$4.86M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$4.25M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.74M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16.7M |
| 2 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$9.43M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$4.89M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.53M |
| 5 |
Walleye Capital
New York
|
-$2.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Belvedere Trading
Chicago,
Illinois
| – | -$83.3K | -17,429 | Closed |
|
|
MA
152
Mutual Advisors
Omaha,
Nebraska
| – | -$83K | -17,366 | Closed |
|
|
GCP
153
GSA Capital Partners
London,
United Kingdom
| – | -$51K | -10,734 | Closed |
|
154
Citadel Advisors
Miami,
Florida
| – | -$14.8K | -2,989 | Closed |
|
155
Group One Trading
Chicago,
Illinois
| – | -$3.68K | -745 | Closed |
|
|
CG
156
Cutler Group
San Francisco,
California
| – | +$494 | +100 | New |
|
CRBU Hedge Fund Activity: Q4 2023 in Review
144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q4 2023, worth a combined $402M — up 19% from $338M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CRBU positions and 12 closed out — a net gain of 18 holders — while 55 added to existing stakes and 31 trimmed.
The largest buyer was Alkeon Capital Management, adding an estimated $7.26M. The largest seller was Deerfield Management, exiting entirely with an estimated $16.7M sold.
- 144 institutional investors held Caribou Biosciences (CRBU) as of Q4 2023, up from 126 in Q3 2023.
- Funds reported $402M of Caribou Biosciences stock for Q4 2023, up 19% quarter-over-quarter.
- 30 funds opened new Caribou Biosciences positions in Q4 2023 and 12 closed out, a net change of +18 holders.
- The largest Caribou Biosciences buyer in Q4 2023 was Alkeon Capital Management, an estimated $7.26M added.
- The largest Caribou Biosciences seller in Q4 2023 was Deerfield Management, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2023.